Deutsche Bank AG Takes $1.26 Million Position in Arvinas, Inc. $ARVN

Key Points

• Deutsche Bank acquired 151,167 Arvinas shares worth approximately $1.26 million, joining other institutional investors that have increased their positions. Institutions collectively own 95.19% of the company.
• Arvinas reported significantly stronger quarterly results, including $249.7 million in revenue—up 1,014.7% year over year—and EPS of $2.58 versus consensus expectations for a loss of $0.37.
• Analyst sentiment remains mixed: the stock carries a consensus “Hold” rating with a $14.17 price target, while shares recently opened at $9.18 and insiders own 7.3% of the company.

Deutsche Bank AG bought a new position in Arvinas, Inc. (NASDAQ:ARVN - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 151,167 shares of the company's stock, valued at approximately $1,256,000. Deutsche Bank AG owned approximately 0.23% of Arvinas as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. AQR Capital Management LLC purchased a new stake in Arvinas in the 1st quarter worth $727,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Arvinas during the first quarter valued at about $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Arvinas by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company's stock worth $271,000 after purchasing an additional 2,122 shares during the last quarter. Millennium Management LLC lifted its position in shares of Arvinas by 208.4% in the first quarter. Millennium Management LLC now owns 1,310,326 shares of the company's stock worth $9,198,000 after buying an additional 885,483 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Arvinas by 108.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company's stock valued at $6,339,000 after buying an additional 469,394 shares during the last quarter. 95.19% of the stock is owned by hedge funds and other institutional investors.

Arvinas Stock Performance

NASDAQ:ARVN opened at $9.18 on Friday. The firm has a market capitalization of $592.30 million, a PE ratio of 91.81 and a beta of 1.71. The stock's fifty day moving average is $8.55 and its 200 day moving average is $9.83. Arvinas, Inc. has a fifty-two week low of $6.97 and a fifty-two week high of $14.51.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of ($0.37) by $2.95. Arvinas had a net margin of 2.94% and a return on equity of 1.91%. The company had revenue of $249.70 million during the quarter, compared to analyst estimates of $60.71 million. During the same period in the previous year, the firm earned ($0.84) earnings per share. Arvinas's quarterly revenue was up 1014.7% compared to the same quarter last year. Equities analysts forecast that Arvinas, Inc. will post 0.05 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on ARVN shares. BTIG Research reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Arvinas in a research note on Tuesday, August 4th. Morgan Stanley set a $10.00 target price on shares of Arvinas in a report on Monday, August 10th. Wedbush boosted their price target on shares of Arvinas from $11.00 to $12.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. Barclays upped their price target on shares of Arvinas from $18.00 to $20.00 and gave the company an "overweight" rating in a research note on Wednesday, May 13th. Finally, Weiss Ratings raised shares of Arvinas from a "sell (e+)" rating to a "sell (d)" rating in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $14.17.

Insider Activity

In related news, CFO Andrew Saik sold 5,696 shares of Arvinas stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $8.16, for a total transaction of $46,479.36. Following the completion of the transaction, the chief financial officer directly owned 187,432 shares of the company's stock, valued at approximately $1,529,445.12. The trade was a 2.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 7.30% of the company's stock.

About Arvinas

Arvinas, Inc NASDAQ: ARVN is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.

The company's most advanced clinical candidates address hormone-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source